GlassScriptPhysician profile
Thomas A Zorn
NPI 1619236619
$2,555.44
in general payments reported to CMS, 2019-2025
21 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $79.80 · 2024: $1,174 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $539.83 | 2023-2025 | |
| Abbvie INC. | $520.08 | 2024-2025 | |
| Novo Nordisk INC | $331.96 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $226.94 | 2023-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.12 | 2024-2025 | Jardiance, Jascayd |
| Astrazeneca Pharmaceuticals LP | $130.55 | 2024-2025 | Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.56 | 2024-2025 | Xifaxan, Relistor, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $86.06 | 2025 | |
| Exact Sciences Corporation | $72.10 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $55.24 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $51.94 | 2025 | Shingrix, Arexvy, Penmenvy |
| Amgen INC. | $47.48 | 2025 | Evenity, Otezla, Repatha |
| Abbott Laboratories | $46.20 | 2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $46.10 | 2025 | Vpriv |
| Kowa Pharmaceuticals America, INC. | $42.98 | 2025 | Zoryve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $33.74 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $27.38 | 2025 | |
| Astellas Pharma US INC | $22.16 | 2025 | Veozah |
| Supernus Pharmaceuticals, INC. | $19.24 | 2025 | Qelbree |
| Neos Therapeutics, LP | $14.43 | 2024 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $14.35 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Zorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.